Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
CGEMthis companyCullinan Therapeutics, Inc.	$11.61	-2.78×	1.5×	0×	-2.39×	-90.4%	0.0%	0.0%	0.0%	-53.8%	-58.7%	-28.8%	0.01×	0.39×	0×	10.25×	0.0%	1	9.54	2	C
ALXOALX Oncology Holdings Inc.	$1.22	-0.59×	2.33×	0×	-0.5×	-90.6%	0.0%	0.0%	0.0%	-391.4%	-262.0%	-139.1%	0.2×	0.11×	-64.93×	2.07×	0.0%	2	-2.66	2	C
AVBPArriVent BioPharma, Inc.	$14.54	-4.66×	2.52×	0×	-4.38×	-92.2%	0.0%	0.0%	0.0%	-54.1%	-57.8%	-20.8%	0×	0.27×	0×	12.83×	0.0%	2	12.15	2	C+
JANXJanux Therapeutics, Inc.	$13.70	-7.54×	0.89×	85.51×	-7.39×	-118.0%	79.7%	-1576.7%	-1136.3%	-11.9%	-16.0%	-9.7%	0.02×	0.27×	0×	39.04×	0.0%	3	8.27	2	C+
LEGNLegend Biotech Corporation	$24.25	-13.59×	4×	3.89×	-15.15×	-9886.0%	60.3%	-13.3%	-28.8%	-29.6%	-9.6%	-4.2%	0.41×	2.1×	-6.38×	1.96×	0.0%	3	4.12	1	C-
MGNXMacroGenics, Inc.	$2.44	-1.36×	1.83×	0.68×	-2.54×	-2714.5%	71.1%	-48.7%	-49.9%	-134.2%	-33.0%	-81.6%	1.92×	-0.83×	-8.56×	5.1×	0.0%	1	-4.43	1	D+
Peer median	—	-4.66×	2.33×	0.68×	-4.38×	-118.0%	60.3%	-13.3%	-28.8%	-54.1%	-33.0%	-20.8%	0.2×	0.27×	-6.38×	5.1×	0.0%	2	4.12	2	—